SAB Biotherapeutics (SABS) Enterprise Value (2020 - 2025)
SAB Biotherapeutics (SABS) has disclosed Enterprise Value for 6 consecutive years, with -$96.6 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Enterprise Value fell 365.27% year-over-year to -$96.6 million, compared with a TTM value of -$96.6 million through Dec 2025, down 365.27%, and an annual FY2025 reading of -$96.6 million, down 365.27% over the prior year.
- Enterprise Value was -$96.6 million for Q4 2025 at SAB Biotherapeutics, up from -$110.9 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$2.4 million in Q3 2023 and bottomed at -$110.9 million in Q3 2025.
- Average Enterprise Value over 5 years is -$29.1 million, with a median of -$18.4 million recorded in 2021.
- The sharpest move saw Enterprise Value crashed 1154.58% in 2024, then surged 84.68% in 2025.
- Year by year, Enterprise Value stood at -$39.5 million in 2021, then skyrocketed by 61.95% to -$15.0 million in 2022, then tumbled by 275.93% to -$56.6 million in 2023, then skyrocketed by 63.3% to -$20.8 million in 2024, then crashed by 365.27% to -$96.6 million in 2025.
- Business Quant data shows Enterprise Value for SABS at -$96.6 million in Q4 2025, -$110.9 million in Q3 2025, and -$5.7 million in Q2 2025.